Matthew D. Massich, who holds a Ph.D. in biological sciences, is a Technical Advisor at Rakoczy Molino Mazzochi Siwik LLP.
Dr. Massich assists with preparation of opinions in the pharmaceutical, chemical, and related fields. He also provides technical litigation support in a wide range of cases, including Hatch-Waxman pharmaceutical cases.
Dr. Massich completed a Ph.D. in Biological Sciences, with concentrations in biotechnology, nanotechnology, and cancer biology, from Northwestern University in 2012.
Prior to joining Rakoczy Molino Mazzochi Siwik LLP, Dr. Massich held a position as a postdoctoral associate at Argonne National Lab. His work included leading research efforts toward the advancement of a highly-specific, tumor-targeted cancer therapy employing titanium dioxide semiconductor nanoparticles to exclusively kill cancer cells and reduce the side effects of current chemotherapeutic methods. While at Northwestern, Dr. Massich’s work included developing and improving nucleic acid-gold nanoparticle conjugates for therapeutic and diagnostic applications, as well as characterizing the cellular response of the nanostructures to ensure their safety for pharmaceutical applications.